Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

August 15, 2019

Parkinson’s UK Awards Scientist £100,000 to ID Ways of Protecting Dopamine-producing Neurons

News

A scientist at the University of Sheffield in England has been awarded a £100,000 grant by Parkinson’s UK to develop a treatment that might slow or stop the progression of ... Read more

August 9, 2019August 9, 2019

Grant Will Help Develop Non-Invasive Skin Test for Diagnosing Parkinson’s

News

Scientist Wenquan Zou, MD, PhD, has received a two-year grant to develop a non-invasive skin test for diagnosing Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative disorders. Diagnosing these disorders ... Read more

August 7, 2019August 7, 2019

Grant from MS Society, Parkinson’s UK to Establish Digital Brain Bank

News

The Multiple Sclerosis (MS) and Parkinson’s Tissue Bank at Imperial College London, is the largest repository of brain and spinal cord tissue samples in Europe. Now, the MS Society ... Read more

July 29, 2019July 29, 2019

CHMP Favors EU Approval of Inbrija to Treat Parkinson’s Off Periods

News

The Committee for Medicinal Products for Human Use (CHMP) — an arm of the European Medicines Agency (EMA) — is recommending that Inbrija, by Acorda Therapeutics, be approved to treat off ... Read more

July 23, 2019July 23, 2019

Imbalance in Dopamine and Acetylcholine Levels May Drive Disease Progression, Study Finds

News

Therapies against motor loss and progression in Parkinson’s’ disease (PD) may need to tackle the imbalance between two neurotransmitters, dopamine and acetylcholine, instead of focusing on dopamine alone, an ... Read more

July 15, 2019July 15, 2019

FDA Accepts New Drug Application for Opicapone as Add-on Therapy

News

The U.S. Food and Drug Administration has accepted Neurocrine Biosciences’ new drug application for opicapone as a potential add-on therapy to levodopa/carbidopa for Parkinson’s disease. The FDA has set a 12-month ... Read more

July 9, 2019July 11, 2019

EVER Pharma Expands European Market for D-mine Pump for Delivering Parkinson’s Therapy

News

D-mine Pump, a portable micro-infusion pump designed to continuously deliver apomorphine under the skin (subcutaneously) to patients with Parkinson’s disease, has received the European CE approval and now will be ... Read more

July 8, 2019July 8, 2019

Seelos Therapeutics Acquires Rights for Parkinson’s Gene Therapy Program

News

Seelos Therapeutics has acquired the rights for a gene therapy program targeting the regulation of the SNCA gene, which provides instructions to make alpha-synuclein, a key player in the ... Read more

June 28, 2019June 28, 2019

$6.6 Million Grant Will Fund Research Into Environmental Cues That May Trigger Parkinson’s

News

Scientist Kim Tieu, PhD has received a $6.6 million grant to investigate the environmental factors that may trigger the death of brain cells in Parkinson’s disease, and to develop therapies that prevent ... Read more

June 21, 2019August 22, 2019

Accordion Pill May Help Reduce Motor Fluctuations in Parkinson’s Disease, Phase 2 Trial Shows

News

The Accordion Pill Carbidopa/Levodopa (AP-CD/LD) administered three times a day reduced the variability of blood plasma levels of levodopa in Parkinson’s disease patients, which suggests that the treatment may ... Read more

Pin It on Pinterest